Generic name: Botulinum Toxin Type A 50[USP'U]
Dosage form: powder, lyophilized, for solution
Medically reviewed by Drugs.com. Last updated on May 9, 2019.
Instructions for Safe Use
The potency Units of XEOMIN (incobotulinumtoxinA) for injection are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method [see Warnings and Precautions (5.2) and Description (11)]. Reconstituted XEOMIN is intended for intramuscular or intra-salivary gland injection only.
The recommended maximum cumulative dose for any indication should not exceed 400 Units in a treatment session.
XEOMIN is injected into the parotid and submandibular glands on both sides (i.e., 4 injection sites per treatment session). The recommended total dose per treatment session is 100 Units. The dose is divided with a ratio of 3:2 between the parotid and submandibular glands (Table 1).
Figure 1: Glands for Injection in Chronic Sialorrhea
|M = Masseter|
Use the following guidelines if locating salivary glands using anatomic landmarks:
- To inject the parotid gland, find the midpoint on the line connecting the tragus and mandible angle (Site A and B, respectively, Figure 1), approximately at the height of the ear lobe. Deliver the injection one finger breadth anterior to this site (Star 1, Figure 1).
- To inject the submandibular gland, find the midpoint between the angle of the mandible and the tip of the chin (Site B and C, respectively, Figure 1). Deliver the injection one finger breadth medial to the inferior surface of the mandible at this site (Star 2, Figure 1).
|Gland(s)||Units Per Side||Total|
|Parotid gland(s)||30 Units||60 Units|
|Submandibular gland(s)||20 Units||40 Units|
|Both Glands||50 Units||100 Units|
The concentration used in the clinical study after reconstitution is 5 Units/0.1mL. The timing for repeat treatment should be determined based on the actual clinical need of the individual patient, and no sooner than every 16 weeks.
Upper Limb Spasticity
The dosage, frequency, and number of injection sites should be tailored to the individual patient based on the size, number, and location of muscles to be treated, severity of spasticity, presence of local muscle weakness, patient's response to previous treatment, and adverse event history with XEOMIN. The frequency of XEOMIN treatments should be no sooner than every 12 weeks. In spasticity patients not previously treated with botulinum toxins, initial dosing should begin at the low end of the recommended dosing range and titrated as clinically necessary. Most patients in clinical studies were retreated between 12-14 weeks.
|Units (Range)||Number of injection sites per muscle|
|Flexor digitorum superficialis||25 Units-100 Units||2|
|Flexor digitorum profundus||25 Units-100 Units||2|
|Flexor carpi radialis||25 Units-100 Units||1-2|
|Flexor carpi ulnaris||20 Units-100 Units||1-2|
|Brachioradialis||25 Units-100 Units||1-3|
|Biceps||50 Units-200 Units||1-4|
|Brachialis||25 Units-100 Units||1-2|
|Pronator quadratus||10 Units-50 Units||1|
|Pronator teres||25 Units-75 Units||1-2|
|Flexor pollicis longus||10 Units-50 Units||1|
|Adductor pollicis||5 Units-30 Units||1|
|Flexor pollicis brevis/Opponens pollicis||5 Units-30 Units||1|
Figure 2: Muscles Involved In Adult Upper Limb Spasticity
The recommended initial total dose of XEOMIN for cervical dystonia is 120 Units. In a placebo-controlled trial utilizing initial XEOMIN doses of 120 Units and 240 Units, no meaningful difference in effectiveness was demonstrated between the doses [see Clinical Studies (14.3)]. In previously treated patients, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the XEOMIN dose.
In the treatment of cervical dystonia, XEOMIN is usually injected into the sternocleidomastoid, levator scapulae, splenius capitis, scalenus, and/or the trapezius muscle(s). This list is not exhaustive, as any of the muscles responsible for controlling head position may require treatment [see Clinical Studies (14.3)]. The dose and number of injection sites in each treated muscle should be individualized based on the number and location of the muscle(s) to be treated, the degree of spasticity/dystonia, muscle mass, body weight, and response to any previous botulinum toxin injections.
The frequency of XEOMIN repeat treatments should be determined by clinical response, but should generally be no more frequent than every 12 weeks [see Clinical Studies (14.3)].
In treatment-naïve patients, the recommended initial total dose of XEOMIN is 50 Units (25 Units per eye). In patients previously treated with a botulinum toxin A, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the XEOMIN dose.
The total dose of XEOMIN should not exceed 100 Units per treatment session (50 Units per eye).
XEOMIN is injected into the lateral and medial orbicularis oculi muscle of the upper lid; lateral canthus and the lateral orbicularis oculi muscle of the lower lid; and the corrugator muscle, if necessary (see Figure 3). The number and location of injections may be changed in response to adverse reactions or based on the patient's response to treatment, but the total dose should not exceed 50 Units per eye.
The frequency of XEOMIN repeat treatments should be determined by clinical response but should generally be no more frequent than every 12 weeks [see Clinical Studies (14.4)].
The total recommended XEOMIN dose is 20 Units per treatment session divided into five equal intramuscular injections of 4 Units each. The five injection sites are: two injections in each corrugator muscle and one injection in the procerus muscle.
Retreatment with XEOMIN should be administered no more frequently than every three months.
Preparation and Reconstitution Technique
Prior to injection, reconstitute each vial of XEOMIN with sterile, preservative-free 0.9% Sodium Chloride Injection, USP [see Dosage Form and Strengths (3)]. A 20-27 gauge short bevel needle is recommended for reconstitution. Draw up an appropriate amount of preservative-free 0.9% Sodium Chloride Injection, USP into a syringe (see Table 3). Clean the exposed portion of the rubber stopper of the vial with alcohol (70%) prior to insertion of the needle. After vertical insertion of the needle through the rubber stopper, the vacuum will draw the saline into the vial. Gently inject any remaining saline into the vial to avoid foam formation. If the vacuum does not pull the saline into the vial, then XEOMIN must be discarded. Remove the syringe from the vial and mix XEOMIN with the saline by carefully swirling and inverting/flipping the vial – do not shake vigorously. Reconstituted XEOMIN is a clear, colorless solution free of particulate matter. XEOMIN should not be used if the reconstituted solution has a cloudy appearance or contains floccular or particulate matter.
After reconstitution, XEOMIN should be used for only one injection session and for only one patient. Reconstituted XEOMIN solution should be administered within 24 hours after dilution. During this time period, unused reconstituted XEOMIN may be stored in the original container in a refrigerator 2°C -8°C (36°F -46°F) for up to 24 hours until time of use. XEOMIN vials are for single-dose only. Discard any unused portion.
Diluent volumes for reconstitution of XEOMIN are indicated in Table 3.
|Volume of Preservative-free 0.9% Sodium Chloride Injection, USP||50 Unit Vial:
Resulting dose in Units per 0.1 mL
|100 Unit Vial:
Resulting dose in Units per 0.1 mL
|200 Unit Vial:
Resulting dose in Units per 0.1 mL
|0.25 mL||20 Units||-||-|
|0.5 mL||10 Units||20 Units||40 Units|
|1 mL||5 Units||10 Units||20 Units|
|1.25 mL||4 Units||8 Units||16 Units|
|2 mL||2.5 Units||5 Units||10 Units|
|2.5 mL||2 Units||4 Units||8 Units|
|4 mL||1.25 Units||2.5 Units||5 Units|
|5 mL||1 Unit||2 Units||4 Units|
Reconstituted XEOMIN is intended for intramuscular or intra-salivary gland injection only.
If proposed injection sites are marked with a pen, the product must not be injected through the pen marks; otherwise a permanent tattooing effect may occur.
For intramuscular injections, the number of injection sites is dependent upon the size of the muscle to be treated and the volume of reconstituted XEOMIN injected.
XEOMIN should be injected carefully when injected at sites close to sensitive structures, such as the carotid artery, lung apices, and esophagus. Before administering XEOMIN, the physician should be familiar with the patient's anatomy and any anatomic alterations, e.g., due to prior surgical procedures.
A sterile needle (e.g., 27-30 gauge (0.30-0.40 mm diameter), 12.5 mm length) should be used for intra-salivary gland administration for the treatment of chronic sialorrhea.
The salivary glands can be located using ultrasound imaging or surface anatomical landmarks [see Dosage and Administration (2.2)].
Upper Limb Spasticity and Cervical Dystonia
A sterile needle (e.g., 26-gauge (0.45 mm diameter), 37 mm length for superficial muscles; or 22-gauge (0.70 mm diameter), 75 mm length for injections into deeper muscles) should be used in the intramuscular administration in the treatment of upper limb spasticity and cervical dystonia.
Localization of the involved muscles with electromyographic guidance or nerve stimulation techniques may be useful.
A sterile needle (e.g., 30-gauge (0.40 mm diameter), 12.5 mm length) should be used in the intramuscular administration in the treatment of blepharospasm.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Xeomin (incobotulinumtoxinA)
- Side Effects
- During Pregnancy
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 2 Reviews
- Drug class: skeletal muscle relaxants
- FDA Approval History